A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC

This study compares the efficacy and safety of AK104 versus Sugemalimab as consolidation therapy in patients with unresectable, locally advanced NSCLC who have not progressed following concurrent or sequential chemoradiotherapy.

Trial Details

NCT ID
NCT06617416
Phase
PHASE3
Sponsor
Akeso
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Cadonilimab (AK104)
  • Sugemalimab
Locations (sample)
  • Jinan, China|36.66833,116.99722

Key Eligibility Criteria

  • Subjects must sign the written informed consent form (ICF) voluntarily.
  • Age ≥18 years.
  • Histologically or cytologically confirmed unresectable locally advanced (Stage III) NSCLC.
  • Absence of known EGFR sensitive mutations and negative for ALK and ROS1 fusions.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →